EXCEMED WORKSHOP
The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge
London, UK - 19 May 2018
The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge

Overview
Autoimmune-mediated diseases affecting the peripheral nervous system (PNS) are a group of pathologies usually associated with an aggressive course and high clinical disability. A prompt diagnosis and correct course of treatment are fundamental in order to limit functional impairment and prevent clinical relapses.

The clinical picture of autoimmune mediated polyneuropathies ranges from the acute inflammatory demyelinating polyneuropathy (AIDP), to the chronic inflammatory demyelinating polyneuropathy (CIDP), with all its sub forms, each with specific clinical presentations. Along with the peripheral nervous system, the neuromuscular plaque can also be affected by antibodies and pathogenic activity, causing myasthenia gravis (MG).

While in some types of autoimmune-mediated PNS diseases the related causative antibodies are well known, among others the pathogenic role of the immune system is only hypothesized. The best treatment approach is to remove auto antibodies targeting the PNS. The gold standard treatment is finalized to quickly removed autoantibodies targeting the PNS.

This workshop will review the main clinical and pathogenic features of immune-mediated PNS disorders and discuss the rationale and utility of therapeutic plasma exchange.

Learning objectives
By attending this live educational workshop, you will be able to:
- Review the main updated knowledge about clinical aspects and immune pathogenesis of inflammatory neuropathies and myasthenia gravis
- Summarize the therapeutic plasma exchange’s mechanisms of action including the effects on the immune system, removal of disease mediators and biomarkers
- Explain the practical utility of plasma exchange in Guillain Barré syndrome and myasthenia gravis
- Implement the daily clinical practice with the current practice guidelines about the indication and use of therapeutic plasma exchange in peripheral nervous system disorders

Target audience
This programme is designed for neurologists specialized in PNS & Neuromuscular, Internal Medicine and ICU, who want to acquire up-to-date information for improving their current practice.

CME Provider
EXCEM ED is a non profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world.

EXCEM ED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACME®) which states that continuing medical education must be balanced, independent, objective and scientifically rigorous.

EXCEM ED - Excellence in Medical Education
Programme Manager: Silvia Cristofanelli
T +39 331 6514233 - F +39 06 420413 677
silvia.cristofanelli@excedmed.org
Medical Advisor: Federica Cerri
cerri.federica@hsr.it

EXCEM ED adheres to the principles of the Good CME Practice group (gCMEp).
Venue
This live educational workshop takes place at the:
Royal College of Physicians
1 St Andrews Pl, NW1 4LE
London, UK

Language
The official language of this live educational workshop is English.

For any logistic inquiry, please contact:
Meridiano Congress International
Congress Manager: David H. Slangen
T +39 06 88595 250 - F +39 06 88595 234
david.slangen@meridiano.it

Continuing medical education
An application has been made to the Royal College of Physicians in London designated for a maximum of 6 (six) hours of CPD credits of the EXCEMED workshop "The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge" held on 19 May 2018 in London, UK.

FACULTY
Anupam Bhattacharjee
Department of Neurology
Royal Free Hospital
London, UK

Saiju Jacob
Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
Birmingham, UK

Simon Rinaldi
Nuffield Department of Clinical Neurosciences
Division of Medical Science
John Radcliffe Hospital
Oxford, UK
## PROGRAMME

### Saturday, 19 May 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.15</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.45</td>
<td>Welcome and introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session I</strong></td>
<td>Clinical and pathogenical aspects of immune-mediated neuromuscular disorders</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>L1</td>
<td>Guillain-Barré syndrome spectrum</td>
<td>S. Rinaldi (UK)</td>
</tr>
<tr>
<td>10.30</td>
<td>L2</td>
<td>Myasthenia gravis clinical overview</td>
<td>S. Jacob (UK)</td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11.15</td>
<td>L3</td>
<td>Antibodies and immune-mediated neuromuscular disorders: what is known/what’s new</td>
<td>S. Rinaldi (UK)</td>
</tr>
<tr>
<td>11.45</td>
<td></td>
<td>Clinical case presentation on differential diagnosis</td>
<td>S. Jacob (UK)</td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td>Lunch break</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session II</strong></td>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td>L4</td>
<td>Therapeutic plasma exchange and the immune system</td>
<td>S. Jacob (UK)</td>
</tr>
<tr>
<td>14.00</td>
<td>L5</td>
<td>Therapeutic plasma exchange in clinical practice</td>
<td>A. Bhattacharjee (UK)</td>
</tr>
<tr>
<td>14.30</td>
<td>L6</td>
<td>The role of therapeutic plasma exchange in acute inflammatory neuropathies: evidence based guidelines</td>
<td>S. Rinaldi (UK)</td>
</tr>
<tr>
<td>15.00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>15.15</td>
<td>L7</td>
<td>Therapeutic plasma exchange in chronic immune-mediated neuromuscular disorders: when, how, how long</td>
<td>A. Bhattacharjee (UK)</td>
</tr>
<tr>
<td>15.45</td>
<td></td>
<td>Round table on therapeutic plasma exchange: experience from the reference neurological centers</td>
<td>A. Bhattacharjee and S. Rinaldi (UK)</td>
</tr>
<tr>
<td>16.45</td>
<td></td>
<td>Closing remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>End of the live educational workshop</td>
<td></td>
</tr>
</tbody>
</table>
EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCMÉ®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

**Anupam Bhattacharjee** Declared no potential conflict of interest

**Saiju Jacob** Declared to be member of a company advisory board, board of directors or other similar group: Alexion Pharmaceutical. He also declared participation in a company sponsored speaker’s bureau: Eisai Ltd.

**Simon Rinaldi** Declared receipt of grants and contracts: Medical Research Council, Association of British Neurologists, GBSCID Foundation International. Declared to be member of a company advisory board, board of directors or other similar group: GAIN charity medical advisory board.

All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This independent programme is made possible thanks to an educational grant received from Terumo BCT.
Improving the patient's life through medical education

www.excemed.org